Harmony Biosciences participated in the Underdog Series panel discussion hosted by Life Science Cares Philadelphia featuring Christopher Molineaux Nyree Oliver and Dan Rhoton on how the company contributes to the Greater Philadelphia community.
Published
Signal category
Presence & Recognition
Quote
“Christopher Molineaux Nyree Oliver and Dan Rhoton have such compelling insights on how we contribute to the Greater Philadelphia community.”
— Cate McCanless|Harmony Biosciences team
Company
Harmony Biosciences
Committed to developing and delivering new therapeutic options for people living with rare neurological diseases.
- Industry
- Pharmaceutical Manufacturing
- Location
- Plymouth Meeting, US
- Company size
- 343 employees
Harmony Biosciences is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative therapies for people living with rare and other neurological diseases with unmet medical needs. Guided by empathy, driven by science, and focused on innovation, we combine a strong commercial foundation with a growing pipeline of differentiated programs designed to advance treatment across multiple neurological conditions. By creating long-term value through scientific innovation, operational excellence, and disciplined execution, we invest in our people, our pipeline, and our mission to help improve patients’ lives. Follow us: Instagram → @harmony_biosciences X → @harmonybio #InHarmony #EmpathyAndInnovation View community guidelines: http://bit.ly/4v2Exc8
Founded 2017